Michael Paukshto, PhD, CTO and co-founder of Fibralign Corporation, was awarded the 2014 Best New Investigator Award at the 11th Biennial NLN International Conference.
Fibralign has developed and established an end-to-end manufacturing system for production of its BioBridge Collagen Matrix in its GMP facility located in Union City, California.
Fibralign Corp. and leading physicians presented an update on clinical findings and case studies during the 30th World Congress of the International Society of Lymphology (ISL), which was held 15-19 October 2025 in Antalya, Turkey. As part of this session, Dr. Corrado...
Fibralign Corp. and its South Korean distributor Healing Solutions, LTD announced today that Good Moonwha Hospital completed its 100th BioBridge case in the surgical treatment of lymphedema. Good Moonhwa is the first medical center in Asia and second worldwide to...
Terumo Corporation announced that the first clinical trial conducted in Japan for evaluation the BioBridge® Collagen Matrix in the surgical treatment of lymphedema has reached its endpoint. Terumo is managing and funding clinical studies in Japan which are being used...